Abbonarsi

A randomized controlled trial of adding intravenous pantoprazole to conventional treatment for the immediate relief of dyspeptic pain - 15/11/12

Doi : 10.1016/j.ajem.2012.02.001 
Khrongwong Musikatavorn, MD a, , Ploykaew Tansangngam, MD b , Suthaporn Lumlertgul, MD b , Atthasit Komindr, MD b
a Emergency Medicine Unit, Department of Medicine, Faculty of Medicine, Chulalongkorn University and King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok 10330, Thailand 
b Emergency Medicine Unit, Outpatient Department, King Chulalongkorn Memorial, Hospital, Thai Red Cross Society, Bangkok 10330, Thailand 

Corresponding author. Tel.: +66 2 256 4553; fax: +66 2 256 4553.

Abstract

Introduction

Acute, severe dyspeptic pain is a common condition in the emergency department. Despite the traditional “GI cocktail” (GI indicates gastrointestinal), an intravenous (IV) proton pump inhibitor (PPI), a novel acid-lowering drug, has recently been used to treat this condition. The aim of this study was to evaluate the immediate effect of IV pantoprazole in addition to the conventional GI cocktail in the relief of severe dyspeptic pain.

Methods

This double-blind, randomized, controlled study was conducted in the emergency department of an urban tertiary-care hospital from January 2011 to October 2011. Selected patients with severe dyspeptic pain were randomized to treatment with a placebo, antacid, and antispasmodic (conventional group) or IV pantoprazole, antacid, and antispasmodic (pantoprazole group). The self-reported 100-mm visual analog scale score, adverse effects, and overall satisfaction were evaluated in 15-minute intervals for 60 minutes.

Results

Eighty-seven eligible cases were enrolled in the study. Forty-four and 43 patients were randomized in the conventional group and pantoprazole group, respectively. There was no difference in the mean 60-minute visual analog scale scores between the treatment groups. The rate of “responders,” additional drug use, adverse effects, and patient satisfaction were similar between the groups.

Conclusion

Intravenous PPI provides no additional benefit over the conventional GI cocktail in the relief of acute, severe dyspeptic pain. Because of its neutral effect and higher cost, the use of IV PPI to treat such conditions should be discouraged in general clinical practice.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Conflict of interest: M.K. received one third of the total amount of intravenous pantoprazole from Merck Sharp & Dohme. The company did not provide other forms of financial support to the study and was not involved in any part of the study design, patient enrollment, data collection and analysis, or manuscript drafting. The authors declared no conflicts of interest. This study was funded by Rachadapiseksompoch Fund Grant No. RA6/54(1), Faculty of Medicine, Chulalongkorn University.


Crown Copyright © 2012  Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 30 - N° 9

P. 1737-1742 - novembre 2012 Ritorno al numero
Articolo precedente Articolo precedente
  • An electrocardiogram technician improves in-hospital first medical contact-to-electrocardiogram times: a cluster randomized controlled interventional trial
  • Raphael van Tulder, Dominik Roth, Christoph Weiser, Benedikt Heidinger, Harald Herkner, Wolfgang Schreiber, Christof Havel
| Articolo seguente Articolo seguente
  • Does ED crowding decrease the number of procedures a physician in training performs? A prospective observational study
  • Clare L. Atzema, R. Alexandra Stefan, Refik Saskin, Greg Michlik, Peter C. Austin

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

@@150455@@ Voir plus

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2026 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.